Sugi Predict

Sugi Predict / Compounds / SCHEMBL6474667

SCHEMBL6474667

SCHEMBL6474667

CC(=O)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.75
▸ KMT2A Q03164 6/20 0.75
▸ MAPT P10636 5/20 0.75
▸ ALDH1A1 P00352 2/20 0.75
▸ TSHR P16473 2/20 0.68
▸ SMN1; SMN2 Q16637 4/20 0.68
▸ SLC2A1 P11166 1/20 0.67
▸ NPC1 O15118 5/20 0.66
▸ RAB9A P51151 5/20 0.66
▸ HTT P42858 4/20 0.66
▸ LMNA P02545 2/20 0.66
▸ IDO1 P14902 1/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.62
▸ KDM4E B2RXH2 1/20 0.62
▸ EGFR P00533 1/20 0.61
▸ CASP3 P42574 1/20 0.59
▸ SENP7 Q9BQF6 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27827876 0.98 MEN1 (0.73) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL5183171 0.93 MEN1 (0.77) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL6815977 0.91 KMT2A (0.86) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL29067505 0.86 NPC1 (0.64) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL30567394 0.86 NPC1 (0.64) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL17601523 0.85 IDO1 (0.65) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL30623277 0.85 IDO1 (0.65) MEN1KMT2AMAPTALDH1A1TSHR
Hydrochloric Acid SCHEMBL27827875 0.84 IDO1 (0.63) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL6815981 0.83 SMN1; SMN2 (0.58) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL11790910 0.83 SLC2A1 (0.69) MEN1KMT2AMAPTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903090-B2 Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal PFIZER (US) 2005-06-07 — — US claimed
US-6828314-B2 Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity PFIZER 2004-12-07 — — US claimed
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives PHARMACIA & UPJOHN COMPANY 2003-12-04 — — US claimed
US-20030220321-A1 Substituted azepino[4,5b]indole derivatives PHARMACIA & UPJOHN COMPANY 2003-11-27 — — US claimed
US-6586421-B2 For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders PHARMACIA & UPJOHN COMPANY 2003-07-01 — — US claimed
EP-1319005-A2 SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-06-18 — — EP claimed
EP-1319004-A2 SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-06-18 — — EP claimed
US-20020107278-A1 Substituted azepino[4,5b]indole derivatives PHARMACIA & UPJOHN COMPANY 2002-08-08 — — US claimed
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives PHARMACIA & UPJOHN COMPANY 2002-06-20 — — US claimed
WO-2002024701-A2 SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 — — WO claimed
WO-2002024700-A2 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 — — WO claimed
JP-61118370-A — — None — — JP disclosed
JP-61205259-A — — None — — JP disclosed
EP-3356345-B1 HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2023-11-08 — — EP disclosed
WO-2023144737-A1 COMPOSITIONS FOR PREVENTING OR TREATING HEART FAILURE (HF) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-03 — — WO disclosed
EP-0183129-A1 Quinolonecarboxylic acid derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 1986-06-04 — — EP disclosed
US-4552879-A BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1985-11-12 — — US disclosed
EP-0049711-B1 PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES BAYER AG (DE) 1984-02-29 — — EP disclosed
US-4399134-A BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1983-08-16 — — US disclosed
EP-0049711-A1 Process for the production of nitro-amino-benzenes BAYER AG (DE) 1982-04-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107278-A1 Substituted azepino[4,5b]indole derivatives HTR5A, HTR1A, HTR1E MEN1 852/4885KMT2A 2844/4885MAPT 2666/4885
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives HTR5A, HTR1A, HTR4 MEN1 959/4885KMT2A 2421/4885MAPT 2537/4885
US-20030220321-A1 Substituted azepino[4,5b]indole derivatives HTR5A, HTR1A, HTR1E MEN1 852/4885KMT2A 2844/4885MAPT 2666/4885
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives HTR5A, HTR1A, HTR4 MEN1 959/4885KMT2A 2421/4885MAPT 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.